Adagio names David Hering permanent CEO with $600K salary, 2M share option; board overhauled

Invivyd, Inc.

David Hering, previously interim CEO and COO, appointed permanent CEO and director effective July 5, 2022.
Hering receives $600K base salary, 60% target bonus, and initial option grant for 2,000,000 shares vesting over 48 months.
Eligible for additional option grant of up to 1,000,000 shares if performance goals achieved by Dec 31, 2022.
Annual meeting elects Tamsin Berry, Marc Elia, Clive Meanwell to board; Marc Elia appointed board chair.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Hering

Chief Executive Officer and Director

IVVD · Invivyd, Inc.

Effective: 2022-07-05
Filed: July 5, 2022, 7:59 PM ET

On July 5, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed David Hering, M.B.A., age 47, as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hering was appointed as Chief Executive Officer and Director at Invivyd, Inc..

Action: appointed
Role: Chief Executive Officer and Director

Exact text from the filing

On July 5, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed David Hering, M.B.A., age 47, as the Company’s Chief Executive Officer.

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-187977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.